Recruiting subjects for acute stroke trials - A meta-analysis

被引:52
作者
Elkins, JS
Khatabi, T
Fung, L
Rootenberg, J
Johnston, SC
机构
[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA
[2] Kaiser Permanente, San Francisco, CA USA
关键词
randomized controlled trials; stroke; acute;
D O I
10.1161/01.STR.0000195149.44390.aa
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose - Recruitment rate is a major determinant of the duration, cost, and feasibility of acute stroke trials. Methods - We performed a meta-analysis of all randomized, controlled trials of >= 300 subjects that were designed to evaluate the efficacy of a medical intervention for the treatment of acute ischemic stroke. Data about trial recruitment, organization, and inclusion/exclusion criteria were abstracted independently by 2 reviewers who applied predefined criteria. Recruitment efficiency was defined as the number of subjects enrolled per study center per month of recruitment. Results - Of 32 trials meeting inclusion criteria, the average recruitment efficiency was 0.79 subjects per center per month (range 0.08 to 3.7). Recruitment efficiency did not vary by geographic region (P = 0.36), but trials conducted in 1 country had more efficient recruitment than international studies (P = 0.03), and recruitment efficiency declined with each percentage increase in the total number of study centers (P = 0.002). The primary study entry criteria that predicted reduced recruitment efficiency were the maximum allowable time from stroke to study enrollment (P = 0.002) and the exclusion of mild strokes (P = 0.009). Trials with a treatment window >6 hours had approximately double the recruitment rates of trials that used treatment windows <= 6 hours (1.03 versus 0.52 patients per center per month). Conclusion - Recruitment rates for acute stroke trials are influenced by organizational structure and study entry criteria. Characterizing predictors of recruitment may help optimize future trial design.
引用
收藏
页码:123 / 128
页数:6
相关论文
共 41 条
[1]   Low molecular weight heparinoid, ORG 10172 (Danaparoid), and outcome after acute ischemic stroke - A randomized controlled trial [J].
Adams, HP ;
Woolson, RF ;
Helgason, C ;
Karanjia, PN ;
Gordon, DL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (16) :1265-1272
[2]   Aptiganel hydrochloride in acute ischemic stroke - A randomized controlled trial [J].
Albers, GV ;
Goldstein, LB ;
Hall, D ;
Lesko, LM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (21) :2673-2682
[3]   Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial [J].
Bath, PMW ;
Lindenstrom, E ;
Boysen, G ;
De Deyn, P ;
Friis, P ;
Leys, D ;
Marttila, R ;
Olsson, JE ;
O'Neill, D ;
Orgogozo, JM ;
Ringelstein, B ;
van der Sande, JJ ;
Turpie, AGG .
LANCET, 2001, 358 (9283) :702-710
[4]   Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study [J].
Berge, E ;
Abdelnoor, M ;
Nakstad, PH ;
Sandset, PM .
LANCET, 2000, 355 (9211) :1205-1210
[5]   CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke [J].
Chen, ZM ;
Hui, JM ;
Liu, LS ;
Liu, ZM ;
Peto, R ;
Sandercock, P ;
Wang, WQ ;
Wang, YX ;
Wang, ZB ;
Xie, JX ;
You, GX ;
Zhang, FL ;
Zhang, HQ ;
Zhao, ZY .
LANCET, 1997, 349 (9066) :1641-1649
[6]   A randomized efficacy trial of citicoline in patients with acute ischemic stroke [J].
Clark, WM ;
Williams, BJ ;
Selzer, KA ;
Zweifler, RM ;
Sabounjian, LA ;
Gammans, RE .
STROKE, 1999, 30 (12) :2592-2597
[7]   A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients [J].
Clark, WM ;
Wechsler, LR ;
Sabounjian, LA ;
Schwiderski, UE .
NEUROLOGY, 2001, 57 (09) :1595-1602
[8]   Cervene (nalmefene) in acute ischemic stroke - Final results of a phase III efficacy study [J].
Clark, WM ;
Raps, EC ;
Tong, DC ;
Kelly, RE .
STROKE, 2000, 31 (06) :1234-1239
[9]   Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].
Clark, WM ;
Wissman, S ;
Albers, GW ;
Jhamandas, JH ;
Madden, KP ;
Hamilton, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026
[10]   Treatment of acute ischemic stroke with piracetam [J].
DeDeyn, PP ;
DeReuck, J ;
Deberdt, W ;
Vlietinck, R ;
Orgogozo, JM .
STROKE, 1997, 28 (12) :2347-2352